1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Inflammatory bowel disease

Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis

Evidence summary [ES35] Published: 24 February 2021

  • Advice
  • Tools and resources
  • Evidence

Evidence

Review and download supporting evidence.

Supporting evidence

  • Evidence review  
  • Evidence review  PDF 419 KB 24 February 2021